Foresee Pharmaceuticals Co., Ltd. (TPEX: 6576)
Taiwan
· Delayed Price · Currency is TWD 79.10
-0.50 (-0.63%)
Sep 10, 2024, 1:30 PM CST
Foresee Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 327.18 | 195.04 | 301.51 | 226.03 | 230.44 | 75.2 | Upgrade
|
| Revenue Growth (YoY) | 248.98% | -35.31% | 33.39% | -1.91% | 206.44% | 188.82% | Upgrade
|
| Cost of Revenue | 163.65 | 81.07 | 25.54 | 50.95 | 57.01 | 17.25 | Upgrade
|
| Gross Profit | 163.53 | 113.97 | 275.97 | 175.08 | 173.43 | 57.95 | Upgrade
|
| Selling, General & Admin | 156.85 | 160.16 | 124.23 | 99.07 | 120.58 | 109.32 | Upgrade
|
| Research & Development | 865.86 | 961.44 | 621.18 | 614.64 | 537.65 | 418.75 | Upgrade
|
| Operating Expenses | 1,023 | 1,122 | 745.41 | 713.71 | 658.23 | 528.07 | Upgrade
|
| Operating Income | -859.18 | -1,008 | -469.44 | -538.63 | -484.79 | -470.13 | Upgrade
|
| Interest Expense | -4.92 | -2.85 | -0.4 | -0.68 | -1 | -0.52 | Upgrade
|
| Interest & Investment Income | 36.24 | 23.53 | 8.34 | 3.53 | 1.04 | 3.2 | Upgrade
|
| Currency Exchange Gain (Loss) | 19.51 | -2.32 | 23.35 | -3.05 | 1.37 | 0.1 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.83 | 0.83 | 1.2 | 10.17 | 0.1 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -807.52 | -988.45 | -436.96 | -528.66 | -483.28 | -467.34 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 0.29 | 0.8 | 0.52 | 0.22 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.03 | -0.2 | -0.31 | -0.13 | -0.06 | -2.86 | Upgrade
|
| Asset Writedown | - | - | -1.16 | - | - | - | Upgrade
|
| Other Unusual Items | 0.21 | 0.01 | - | - | - | - | Upgrade
|
| Pretax Income | -807.34 | -988.64 | -438.13 | -527.99 | -482.81 | -469.98 | Upgrade
|
| Income Tax Expense | 51.65 | 47.67 | 34.51 | 41.28 | 27.9 | 17.23 | Upgrade
|
| Net Income | -859 | -1,036 | -472.64 | -569.27 | -510.71 | -487.21 | Upgrade
|
| Net Income to Common | -859 | -1,036 | -472.64 | -569.27 | -510.71 | -487.21 | Upgrade
|
| Shares Outstanding (Basic) | 136 | 127 | 118 | 117 | 101 | 96 | Upgrade
|
| Shares Outstanding (Diluted) | 136 | 127 | 118 | 117 | 101 | 96 | Upgrade
|
| Shares Change (YoY) | 14.84% | 7.82% | 0.57% | 15.74% | 5.71% | 13.86% | Upgrade
|
| EPS (Basic) | -6.32 | -8.14 | -4.00 | -4.85 | -5.04 | -5.08 | Upgrade
|
| EPS (Diluted) | -6.32 | -8.14 | -4.00 | -4.85 | -5.04 | -5.08 | Upgrade
|
| Free Cash Flow | -824.27 | -933.84 | -291.29 | -220.19 | -687.58 | -534.34 | Upgrade
|
| Free Cash Flow Per Share | -6.06 | -7.34 | -2.47 | -1.88 | -6.78 | -5.57 | Upgrade
|
| Gross Margin | 49.98% | 58.44% | 91.53% | 77.46% | 75.26% | 77.06% | Upgrade
|
| Operating Margin | -262.60% | -516.63% | -155.70% | -238.30% | -210.38% | -625.18% | Upgrade
|
| Profit Margin | -262.54% | -531.33% | -156.76% | -251.86% | -221.63% | -647.91% | Upgrade
|
| Free Cash Flow Margin | -251.93% | -478.80% | -96.61% | -97.42% | -298.38% | -710.58% | Upgrade
|
| EBITDA | -797.67 | -950.68 | -429.72 | -498.38 | -446.65 | -443.56 | Upgrade
|
| EBITDA Margin | -243.80% | - | -142.53% | -220.50% | -193.82% | - | Upgrade
|
| D&A For EBITDA | 61.52 | 56.95 | 39.72 | 40.24 | 38.14 | 26.56 | Upgrade
|
| EBIT | -859.18 | -1,008 | -469.44 | -538.63 | -484.79 | -470.13 | Upgrade
|
| EBIT Margin | -262.60% | - | -155.70% | -238.30% | -210.38% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.